Vir Biotechnology ( NASDAQ:VIR – Get Free Report ) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The firm had revenue of $1.21 million for the quarter, compared to analysts' expectations of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The company's quarterly revenue was down 60.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.02) EPS. Equities research analysts anticipate that Vir Biotechnology will post -3.92 earnings per share for the current year.